Tricyclic antidepressants

35,090views

Tricyclic antidepressants

DNP 673

DNP 673

Mood disorders: Clinical
Anxiety disorders: Clinical
Schizophrenia spectrum disorders: Clinical
Dissociative disorders: Clinical
Eating disorders: Clinical
Obsessive compulsive disorders: Clinical
Trauma- and stressor-related disorders: Clinical
Disruptive, impulse-control and conduct disorders: Clinical
Personality disorders: Clinical
Sleep disorders: Clinical
Somatic symptom disorders: Clinical
Sexual dysfunctions: Clinical
Paraphilic disorders: Clinical
Dementia and delirium: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Substance misuse and addiction: Clinical
Psychiatric emergencies: Pathology review
Schizophrenia spectrum disorders: Pathology review
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Drug misuse, intoxication and withdrawal: Stimulants: Pathology review
Drug misuse, intoxication and withdrawal: Alcohol: Pathology review
Drug misuse, intoxication and withdrawal: Other depressants: Pathology review
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Major depressive disorder
Suicide
Bipolar and related disorders
Major depressive disorder with seasonal pattern
Premenstrual dysphoric disorder
Generalized anxiety disorder
Social anxiety disorder
Panic disorder
Agoraphobia
Phobias
Obsessive-compulsive disorder
Body focused repetitive disorders
Body dysmorphic disorder
Post-traumatic stress disorder
Physical and sexual abuse
Schizoaffective disorder
Schizophreniform disorder
Delusional disorder
Schizophrenia
Delirium
Amnesia
Dissociative disorders
Anorexia nervosa
Bulimia nervosa
Cluster A personality disorders
Cluster B personality disorders
Cluster C personality disorders
Somatic symptom disorder
Factitious disorder
Tobacco use disorder
Opioid use disorder
Cannabis use disorder
Cocaine use disorder
Alcohol use disorder
Bruxism
Nocturnal enuresis
Insomnia
Night terrors
Narcolepsy (NORD)
Erectile dysfunction
Male hypoactive sexual desire disorder
Orgasmic dysfunction
Female sexual interest and arousal disorder
Genito-pelvic pain and penetration disorder
Attention deficit hyperactivity disorder
Disruptive, impulse control, and conduct disorders
Learning disability
Fetal alcohol syndrome
Tourette syndrome
Autism spectrum disorder
Rett syndrome
Enuresis
Serotonin syndrome
Neuroleptic malignant syndrome
Mood disorders: Pathology review
Amnesia, dissociative disorders and delirium: Pathology review
Personality disorders: Pathology review
Eating disorders: Pathology review
Psychological sleep disorders: Pathology review
Malingering, factitious disorders and somatoform disorders: Pathology review
Anxiety disorders, phobias and stress-related disorders: Pathology Review
Trauma- and stress-related disorders: Pathology review
Developmental and learning disorders: Pathology review
Childhood and early-onset psychological disorders: Pathology review

Flashcards

Tricyclic antidepressants

0 of 12 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 2 complete

USMLE® Step 2 style questions USMLE

0 of 6 complete

An 8-year-old is brought to the pediatrician by their parents for bedwetting, which occurs around 2-3 times per week. The patient has tried avoiding fluid intake three hours prior to bedtime, enuresis alarms, and desmopressin therapy; however, the symptoms have persisted. The patient has two older siblings, both of whom were toilet trained by the age of 4 years old. The patient has no other medical conditions and has been meeting all other developmental milestones. Temperature is 37.2°C (99.0°F), pulse is 60/min, and blood pressure is 104/65. Physical examination reveals a well-nourished child who is at the 75 percentile for height and weight. Examination of the penis and testes reveals no significant findings. Urinalysis is unremarkable. Which of the following would be the next best step in management?  

Transcript

Watch video only

Tricyclic antidepressants, or TCAs, are mainly used to treat major depressive disorder.

This disorder causes a persistent feeling of sadness and loss of interest in everyday activities.

Even though the exact cause of depression is still unknown, there's some evidence that suggests it’s related to low levels of neurotransmitters like serotonin, norepinephrine, and dopamine.

Tricyclic antidepressants work by increasing the levels of serotonin and norepinephrine to alleviate the symptoms of depression.

Alright, now within the brain, there are many different types of neurons, but we’re just going to focus on two: serotonergic neurons which produce serotonin, and noradrenergic neurons which produces norepinephrine.

Each of these neurons synthesizes and stores their neurotransmitters in small vesicles.

So, when an action potential reaches the presynaptic membrane, these vesicles fuse with the membrane, releasing neurotransmitters into the synaptic cleft.

Once released, serotonin or 5-HT binds to 5-HT2 receptors on the postsynaptic membrane, thereby increasing neural stimulation and regulating mood, feeding, and reproductive behavior.

On the other hand, norepinephrine binds to norepinephrine receptors on the postsynaptic membrane, boosting alertness.

As long as there’s a high enough concentration of neurotransmitters in the synaptic cleft, the postsynaptic neurons will continue to fire.

Now, serotonergic neurons, on their presynaptic membrane, have serotonin transporters or SERT, while noradrenergic neurons have norepinephrine transporters or NET.

These membrane proteins transport the serotonin and norepinephrine in the synaptic cleft back into presynaptic neurons.

This leads to decreased neurotransmitter concentration within the synaptic cleft, causing the postsynaptic neurons to stop firing.

So, in conditions such as major depressive disorder, tricyclic antidepressants can be used to increase the levels of serotonin and norepinephrine.

Tricyclic antidepressants are subdivided into 2 main groups: tertiary TCAs, which include amitriptyline, imipramine, and clomipramine; and secondary TCAs, which include desipramine and nortriptyline.

Tertiary TCAs are also known as non-selective tricyclic antidepressants and they inhibit both serotonin transporters and norepinephrine transporters, while secondary TCAs, which are also known as selective tricyclic antidepressants, inhibit only norepinephrine transporters.

This way, tricyclic antidepressants are increasing levels of serotonin and norepinephrine or just norepinephrine within the synaptic cleft, thus increasing the activity of postsynaptic neurons.

It's important to note that these medications are slow-acting because it takes time for serotonin and norepinephrine to accumulate within the synaptic cleft. Because of this, it usually takes 2-4 weeks before improvements can be seen.

Even though they’re very effective in the treatment of depression, tricyclic antidepressants are not considered as the first line therapy due to their severe side effects.

They’re typically reserved for when there is no response to other antidepressants, such as selective serotonin reuptake inhibitors, or SSRIs.

Other indications for TCAs include phobic disorders, chronic neuropathic pain, like peripheral neuropathy, and as migraine prophylaxis.

Now, for medication specific indications, clomipramine can be used in the treatment of obsessive-compulsive disorder, or OCD, while imipramine is used in the treatment of nocturnal enuresis, which is involuntary urination while asleep.

Besides serotonin and norepinephrine transporters, TCAs also block histamine H1 receptors, causing sedation; alpha 1 receptors, causing orthostatic hypotension; and muscarinic receptors, causing atropine-like side effects.

Atropine-like side effects occur more commonly with tertiary TCAs and they include dry mouth, tachycardia, urinary retention, confusion, and hallucinations.

TCAs can also cause serotonin syndrome, which is a life-threatening condition caused by serotonin accumulation and over stimulation of the nervous system.

Key Takeaways

Tricyclic antidepressants (TCAs) are a class of medications used to treat depression, anxiety disorders, migraine, and chronic pain. They are named for their chemical structure, which includes three rings of atoms.

TCAs work by preventing serotonin and norepinephrine reuptake from the synaptic cleft, thus enhancing the effect of both neurotransmitters on postsynaptic neurons. Some common TCAs include amitriptyline, imipramine, and nortriptyline.

Common side effects include dry mouth, blurred vision, constipation, dizziness, and drowsiness. TCAs can also cause more serious side effects, such as heart rhythm disturbances, seizures, and an increased risk of suicide, particularly in younger individuals.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Mechanism of action of antidepressant medications" J Clin Psychiatry (1990)
  5. "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated" British Journal of Pharmacology (2007)
  6. "Tricyclic antidepressant overdose: a review" Emerg Med J (2001)
  7. "Neuroleptic malignant syndrome and serotonin syndrome" Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II (2018)